BioCentury | Aug 3, 2015
Company News

Zhejiang Wansheng Pharmaceutical, 3SBio deal

...recombinant erythropoietin (EPO) to treat anemia associated with chemotherapy or chronic kidney disease (CKD), and TPIAO...
BioCentury | Jul 25, 2015
Company News

3SBio acquires Zhejiang Wansheng

...recombinant erythropoietin (EPO) to treat anemia associated with chemotherapy or chronic kidney disease (CKD), and TPIAO...
BioCentury | Jun 11, 2015
Financial News

3SBio raises HK$4.4B in Hong Kong IPO

...recombinant erythropoietin (EPO) to treat anemia associated with chemotherapy or chronic kidney disease (CKD), and TPIAO...
BioCentury | Mar 2, 2015
Finance

China's 3SBio plans 2nd IPO

...recombinant erythropoietin (EPO) to treat anemia associated with chemotherapy or chronic kidney disease (CKD), and TPIAO...
BioCentury | Feb 24, 2015
Financial News

China's 3SBio aims to go public again

...recombinant erythropoietin (EPO) to treat anemia associated with chemotherapy or chronic kidney disease (CKD), and TPIAO...
BioCentury | Mar 18, 2013
Product Development

Bettering China's biosimilars

...MS). Additionally, 3SBio Inc. markets EPIAO injectable recombinant human erythropoietin (EPO) to treat anemia and TPIAO...
BioCentury | Jan 31, 2011
Clinical News

TPIAO regulatory update

...China's State Food and Drug Administration (SFDA) approved an expanded label for TPIAO to include treatment...
...human thrombopoietin is already marketed to treat chemotherapy-induced thrombocytopenia. 3SBio Inc. (NASDAQ:SSRX), Shenyang, China Product: TPIAO...
BioCentury | Jan 10, 2011
Strategy

Gateway Deals in China

...to treat anemia associated with chemotherapy and anemia in patients with chronic kidney disease (CKD); TPIAO...
...company has 11 programs in development, with three in registration for SFDA approval: high-dose EPIAO; TPIAO...
BioCentury | Mar 23, 2009
Clinical News

TPIAO regulatory update

...application to the Chinese State Food and Drug Administration (SFDA) to expand the label for TPIAO...
...human thrombopoietin is already marketed to treat chemotherapy-induced thrombocytopenia. 3SBio Inc. (NASDAQ:SSRX), Shenyang, China Product: TPIAO...
BioCentury | Mar 17, 2008
Regulation

ITP pipeline

...NYSE:GSK)/ Ligand (NASDAQ:LGND) Promacta eltrombopag Non-peptide small molecule thrombopoietin (TPO) receptor agonist Registration 3SBio (NASDAQ:SSRX) TPIAO...
Items per page:
1 - 10 of 15